ClinicalTrials.gg
CompletedNCT01215786Updated Aug 17, 2015Results posted

Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

A Phase 1 interventional study of AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo) and timolol ophthalmic solution 0.5% in Glaucoma, Open-Angle and Ocular Hypertension, sponsored by Allergan. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-08-17.

Sponsored by Allergan (part of AbbVie) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies testing timolol in Glaucoma, Open-Angle — none open to participants now, none under way, none of them phase 3. Timolol · Glaucoma, Open-Angle.

Enrollment
16th of 24
50 · median 77
Started
2010
with 1 other
Phase 1
Only one
of the 24
Registered
13th of 24
by date
Lead sponsor
4 of 24
Allergan

Among the 24 studies testing timolol in Glaucoma, Open-Angle, this one is the 16th largest by enrollment, is one of 2 that started in 2010, is the only one in phase 1, and was the 13th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

None of the 24 studies testing timolol in Glaucoma, Open-Angle is open now. The open studies under Glaucoma, Open-Angle, anywhere →

About timolol

Timolol: first FDA approval 1978 (TIMOPTIC), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 24 studies testing timolol in Glaucoma, Open-Angle as a file.
02

Study summary

This is an exploratory study that will evaluate the safety and pharmacodynamics of up to 3 doses of AGN-207281 based on an ongoing review of data during the study period compared with timolol ophthalmic solution or placebo in patients with ocular hypertension or primary open-angle glaucoma.

03

Conditions studied

  • Glaucoma, Open-Angle
  • Ocular Hypertension
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ocular hypertension or primary open-angle glaucoma in each eye
  • Requires IOP-lowering therapy in both eyes
  • Visual acuity score of 20/100 or better in each eye

Exclusion criteria

Exclusion Criteria:

  • Experienced significant weight change (over 10 pounds) within 60 days
  • History of alcohol or drug addiction
  • History of migraines or frequent headaches
  • Anticipated wearing of contact lenses during the study
  • Required chronic use of ocular medications during study
  • Eye surgery within 6 months
  • Use of systemic beta blockers (eg, atenolol, propranolol) within 2 months
  • Use of oral, intramuscular, intravenous within 21 days
  • Use of ophthalmic corticosteroids within 2 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Other
    AGN-207281 ophthalmic solution

    AGN-207281 0.1% ophthalmic solution on Days 1-7 and AGN-207281 0.3% ophthalmic solution on Days 8-14

    Drug: AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo)

  • Active comparator
    Timolol ophthalmic solution 0.5%

    timolol ophthalmic solution 0.5%

    Drug: timolol ophthalmic solution 0.5%

  • Placebo comparator
    Placebo

    AGN-207281 vehicle ophthalmic solution (Placebo)

    Drug: AGN-207281 vehicle ophthalmic solution (Placebo)

Interventions

  • DrugAGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo)

    One drop of AGN-207281 ophthalmic solutions (0.1% on Days 1-7 and 0.3% on Days 8-14) instilled to both eyes in the morning followed by one drop of AGN-207281 vehicle ophthalmic solution (placebo) instilled to both eyes in the evening for 13 days.

  • One drop of timolol ophthalmic solution 0.5% instilled to both eyes, in the morning for 14 days, and in the evening for 13 days

  • DrugAGN-207281 vehicle ophthalmic solution (Placebo)

    One drop of AGN-207281 vehicle ophthalmic solution instilled to both eyes, in the morning for 14 days and in the evening for 13 days.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Day 14

    Change from baseline in worse eye IOP at day 14. Worse eye IOP refers to the eye with the worse (highest) baseline IOP (a measurement of the fluid pressure inside the eye). A negative number change from baseline indicates a reduction in IOP (improvement).

    Time frame: Baseline, Day 14

Secondary outcomes

  1. Mean Concentration of AGN-207281 in Plasma at Day 7

    Mean concentration of AGN-207281 in plasma at day 7. Plasma is the liquid component of the blood in which the blood cells are suspended. On day 7, the plasma sample collected 15 minutes post-morning dose from each patient receiving AGN-207281 was analyzed to determine the average drug concentration levels of AGN-207281.

    Time frame: Day 7

  2. Mean Concentration of AGN-207281 in Plasma at Day 14

    Mean concentration of AGN-207281 in plasma at day 14. Plasma is the liquid component of the blood in which the blood cells are suspended. On day 14, the plasma sample collected 15 minutes post-morning dose from each patient receiving AGN-207281 was analyzed to determine the average drug concentration levels of AGN-207281.

    Time frame: Day 14

07

Results

Posted Jan 16, 2012

Participant flow

Participant flow — Overall Study
MilestoneAGN-207281 Ophthalmic SolutionTimolol Ophthalmic Solution 0.5%Placebo
Started211910
Completed211910
Not completed000

Outcome measures

PrimaryChange From Baseline in Worse Eye Intraocular Pressure (IOP) at Day 14

Change from baseline in worse eye IOP at day 14. Worse eye IOP refers to the eye with the worse (highest) baseline IOP (a measurement of the fluid pressure inside the eye). A negative number change from baseline indicates a reduction in IOP (improvement).

Time frame:
Baseline, Day 14
Reported as:
Mean · Millimeters of mercury (mm Hg)
Change From Baseline in Worse Eye Intraocular Pressure (IOP) at Day 14
Millimeters of mercury (mm Hg)AGN-207281 Ophthalmic SolutionTimolol Ophthalmic Solution 0.5%Placebo
Baseline, Hour 025.98 ± 2.58126.58 ± 2.67326.45 ± 2.661
Baseline, Hour 225.93 ± 3.20726.61 ± 3.12526.30 ± 2.781
Baseline, Hour 824.69 ± 2.61024.82 ± 2.57825.25 ± 2.889
Change from Baseline at Day 14, Hour 0-4.17 ± 2.825-6.16 ± 3.189-1.10 ± 2.039
Change from Baseline at Day 14, Hour 2-4.38 ± 3.244-6.08 ± 2.955-1.75 ± 2.690
Change from Baseline at Day 14, Hour 8-4.02 ± 2.826-4.00 ± 3.000-1.70 ± 1.814
SecondaryMean Concentration of AGN-207281 in Plasma at Day 7

Mean concentration of AGN-207281 in plasma at day 7. Plasma is the liquid component of the blood in which the blood cells are suspended. On day 7, the plasma sample collected 15 minutes post-morning dose from each patient receiving AGN-207281 was analyzed to determine the average drug concentration levels of AGN-207281.

Time frame:
Day 7
Reported as:
Mean · Picograms per milliliter (pg/mL)
Mean Concentration of AGN-207281 in Plasma at Day 7
Picograms per milliliter (pg/mL)AGN-207281 Ophthalmic SolutionTimolol Ophthalmic Solution 0.5%Placebo
Mean Concentration of AGN-207281 in Plasma at Day 7177 ± 113——
SecondaryMean Concentration of AGN-207281 in Plasma at Day 14

Mean concentration of AGN-207281 in plasma at day 14. Plasma is the liquid component of the blood in which the blood cells are suspended. On day 14, the plasma sample collected 15 minutes post-morning dose from each patient receiving AGN-207281 was analyzed to determine the average drug concentration levels of AGN-207281.

Time frame:
Day 14
Reported as:
Mean · Picograms per milliliter (pg/mL)
Mean Concentration of AGN-207281 in Plasma at Day 14
Picograms per milliliter (pg/mL)AGN-207281 Ophthalmic SolutionTimolol Ophthalmic Solution 0.5%Placebo
Mean Concentration of AGN-207281 in Plasma at Day 14540 ± 263——

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AGN-207281 Ophthalmic Solution—0/21 (0%)9/21 (42.9%)
Timolol Ophthalmic Solution 0.5%—0/19 (0%)19/19 (100%)
Placebo—0/10 (0%)2/10 (20%)
Most frequent other events
Most frequent other events
EventAGN-207281 Ophthalmic SolutionTimolol Ophthalmic Solution 0.5%Placebo
Eye irritationEye disorders7/218/190/10
Punctate keratitisEye disorders0/214/190/10
Lacrimation increasedEye disorders1/212/190/10
Back painMusculoskeletal and connective tissue disorders0/210/191/10
Foreign body sensation in eyesEye disorders0/210/191/10
Eye painEye disorders1/211/190/10
Eye dischargeEye disorders0/211/190/10
Vision blurredEye disorders0/211/190/10
Joint sprainInjury, poisoning and procedural complications0/211/190/10
HeadacheNervous system disorders0/211/190/10

Baseline characteristics

Age, Customized
Age, Customized(participants)AGN-207281 Ophthalmic SolutionTimolol Ophthalmic Solution 0.5%PlaceboTotal
<45 years0011
Between 45 and 65 years77216
>65 years1412733
Sex: Female, Male
Sex: Female, Male(Participants)AGN-207281 Ophthalmic SolutionTimolol Ophthalmic Solution 0.5%PlaceboTotal
Female138728
Male811322
08

Study locations

1 site
  • Newport Beach, California, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2012, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2010
First posted
Oct 7, 2010
Start
Oct 2010
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Results first posted
Jan 16, 2012
Last update
Aug 17, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01215786
Lead sponsor
Allergan
Responsible party
Sponsor
First posted
Oct 7, 2010
Start date
Oct 2010
Primary completion
Dec 2010
Completion
Dec 2010
Results posted
Jan 16, 2012
Last update
Aug 17, 2015

Study contacts

Medical Director
study director · Allergan

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Timolol

Start the discussion